A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

NCT04034095 · clinicaltrials.gov ↗

COMPLETED

Status

979

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Androgen-deprivation Therapy (ADT)
DRUG: Bicalutamide
DRUG: Abiraterone
DRUG: Prednisolone
DRUG: Docetaxel
DRUG: Enzalutamide
DRUG: Apalutamide

Sponsor

Janssen Pharmaceutical K.K.